東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Fibrinogen Vlissingen/Frankfurt IV: ...

Hogan, Kelly Ann.

FindBook

Google Book

Amazon

博客來

Fibrinogen Vlissingen/Frankfurt IV: Studies with recombinant fibrinogen and gene-targeted mice.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Fibrinogen Vlissingen/Frankfurt IV: Studies with recombinant fibrinogen and gene-targeted mice./
作者:	Hogan, Kelly Ann.
面頁冊數:	143 p.
附註:	Source: Dissertation Abstracts International, Volume: 62-03, Section: B, page: 1152.
Contained By:	Dissertation Abstracts International62-03B.
標題:	Agriculture, Animal Pathology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3007815
ISBN:	0493172793

Fibrinogen Vlissingen/Frankfurt IV: Studies with recombinant fibrinogen and gene-targeted mice.
Hogan, Kelly Ann.

Fibrinogen Vlissingen/Frankfurt IV: Studies with recombinant fibrinogen and gene-targeted mice. - 143 p.

Source: Dissertation Abstracts International, Volume: 62-03, Section: B, page: 1152.

Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2001.

Fibrinogen is the key structural protein involved in blood coagulation and consists of six polypeptide chains (Aalpha, Bbeta, gamma)2 . The dysfibrinogen Vlissingen/Frankfurt IV (V/F IV) is characterized as a deletion of Asn319 and Asp320 from the C-terminus of the gamma-chain of fibrinogen. This dysfibrinogen, which was identified in several family members who are all heterozygous for the inframe 6 db deletion, is associated with both venous and arterial thrombosis. Here, we describe the generation of both human recombinant fibrinogen and gene-targeted mice containing the V/F IV deletion.

ISBN: 0493172793Subjects--Topical Terms:

1021764
Agriculture, Animal Pathology.

Fibrinogen Vlissingen/Frankfurt IV: Studies with recombinant fibrinogen and gene-targeted mice.
LDR:03188nmm 2200301 4500 001 1811179
005 20051203081801.5
008 130610s2001 eng d
020 $a 0493172793
035 $a (UnM)AAI3007815
035 $a AAI3007815
040 $a UnM $c UnM
100 1 $a Hogan, Kelly Ann. $3 1900768
245 1 0 $a Fibrinogen Vlissingen/Frankfurt IV: Studies with recombinant fibrinogen and gene-targeted mice.
300 $a 143 p.
500 $a Source: Dissertation Abstracts International, Volume: 62-03, Section: B, page: 1152.
500 $a Adviser: Susan T. Lord.
502 $a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2001.
520 $a Fibrinogen is the key structural protein involved in blood coagulation and consists of six polypeptide chains (Aalpha, Bbeta, gamma)2 . The dysfibrinogen Vlissingen/Frankfurt IV (V/F IV) is characterized as a deletion of Asn319 and Asp320 from the C-terminus of the gamma-chain of fibrinogen. This dysfibrinogen, which was identified in several family members who are all heterozygous for the inframe 6 db deletion, is associated with both venous and arterial thrombosis. Here, we describe the generation of both human recombinant fibrinogen and gene-targeted mice containing the V/F IV deletion.
520 $a The recombinant fibrinogen did not polymerize; this loss of normal polymerization was due to the lack of "A-a" interactions. Moreover, functions associated with the C-terminal end of the gamma chain, such as platelet aggregation and Factor XIII cross-linking, were also disrupted, suggesting that this deletion of two residues affected the overall structure of the C-terminal domain of the gamma-chain. We found that polymerization of a 1:1 mixture of variant and normal fibrinogen was the same as polymerization of a 1:1 mixture of buffer and normal fibrinogen, indicating that the variant molecules did not incorporate into a normal clot. Because there are two copies of each polypeptide per molecule, we concluded that the heterozygous V/F IV plasma fibrinogen is a mix of homodimers and heterodimers, such that the incorporation of heterodimers into the fibrin clot impairs polymerization. We suggest that incorporation of heterodimers can induce clinical symptoms.
520 $a Analysis of fibrinogen from V/F IV gene-targeted mice demonstrated that the calcium binding site and the "a" are disrupted by the deletion, similar to the human protein. The heterozygous mice provide the first opportunity to examine the association of thrombophilia and dysfibrinogenemia on a controlled genetic background. To date, these mice do not have overt thrombotic disease, but further examination is required. In contrast, the homozygous mice have a bleeding phenotype, evident within the first few days of birth. Unexpectedly, the mutation affected the concentration of fibrinogen in plasma, making this the first hypodysfibrinogenemia modeled in mice.
590 $a School code: 0153.
650 4 $a Agriculture, Animal Pathology. $3 1021764
650 4 $a Chemistry, Biochemistry. $3 1017722
690 $a 0476
690 $a 0487
710 2 0 $a The University of North Carolina at Chapel Hill. $3 1017449
773 0 $t Dissertation Abstracts International $g 62-03B.
790 1 0 $a Lord, Susan T., $e advisor
790 $a 0153
791 $a Ph.D.
792 $a 2001
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3007815